Eupraxia transfers to Nasdaq Global Select
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The transfer to a higher market tier may enhance the company's visibility and liquidity, potentially attracting more institutional investors. The announcement of conference participation could increase investor engagement and interest in the company's clinical programs.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, announced that its common shares commenced trading on the Nasdaq Global Select Market, the highest tier of Nasdaq, effective September 8, 2026. The shares previously traded on the Nasdaq Capital Market and continue under the ticker symbol 'EPRX'. The company's listing on the Toronto Stock Exchange remains unchanged. Management will participate in upcoming investor conferences including Cantor Global Healthcare Conference, H.C. Wainwright 28th Annual Global Investment Conference, and Morgan Stanley 24th Annual Global Healthcare Conference. The transfer reflects the company's progress and growth, according to CFO Alex Rothwell.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard